110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
21 citations
,
May 2016 in “The Cochrane library” This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.
16 citations
,
November 2015 in “International Journal of Dermatology” This study found that alopecia significantly reduces quality of life among South African Black women, with subjective symptoms and self-image concerns having the greatest impact.
26 citations
,
September 2015 in “Journal of The American Academy of Dermatology” In this study, spironolactone was reported to stabilize or improve female pattern hair loss in 74.3% of treated women, especially those with signs of hyperandrogenism.
42 citations
,
July 2015 in “Journal of The American Academy of Dermatology” This review discusses diagnostic and treatment considerations for women with cutaneous hyperandrogenism, noting therapeutic options are more effective for hirsutism and acne than for androgenetic alopecia, but reports no new clinical results.
11 citations
,
December 2014 in “Clinical Obstetrics and Gynecology” This article presents a systematic approach for obstetricians/gynecologists to diagnose and manage common types of nonscarring hair loss in women, reporting no new clinical results.
151 citations
,
May 2014 in “American Journal of Clinical Dermatology” This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.
9 citations
,
January 2014 in “Annals of Dermatology” In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.
32 citations
,
January 2014 in “Indian Journal of Dermatology, Venereology and Leprology” This study found that both finasteride and dutasteride effectively increased hair thickness in women with androgenetic alopecia over three years, with dutasteride performing better in women under 50 at specific scalp sites.
42 citations
,
August 2013 in “International Journal of Women's Health” This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.
83 citations
,
December 2012 in “International journal of endocrinology and metabolism/International journal of endocrinology and metabolism.” This article reviews the diverse clinical applications of oral contraceptives beyond birth control, suggesting their effectiveness in treating various female health disorders and conditions.
46 citations
,
October 2012 in “Dermatologic Clinics” This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.
40 citations
,
October 2012 in “British Journal of Dermatology” This review assessed available treatments for female pattern hair loss and found that minoxidil improved hair regrowth compared to placebo, though high-quality evidence was limited for other interventions.
18 citations
,
August 2012 in “Journal of The American Academy of Dermatology” This report describes a case where a sex reassignment patient on estrogen therapy experienced complete hair regrowth on a previously fully alopecic scalp.
35 citations
,
May 2012 in “Cochrane Database of Systematic Reviews” This review found evidence supporting the effectiveness and safety of topical minoxidil for treating female pattern hair loss, though many included studies were at high risk of bias.
10 citations
,
January 2012 in “Annals of Dermatology” In this study, 1.25 mg daily finasteride for 28 weeks showed minimal increase in hair density and thickness in normoandrogenic female pattern hair loss, but no significant clinical improvement was observed.
75 citations
,
December 2011 in “British Journal of Dermatology” This review discusses female pattern hair loss, its psychological impact, and available treatments but provides no new clinical findings; the authors emphasize early intervention for better outcomes.
42 citations
,
April 2011 in “Annals of Pharmacotherapy” This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.
87 citations
,
March 2011 in “Australasian Journal of Dermatology” This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.
30 citations
,
March 2011 in “Australasian Journal of Dermatology” This case report found that a woman's hair loss, which progressed while using spironolactone and topical minoxidil, reversed after switching to flutamide therapy.
64 citations
,
June 2010 in “Journal of The European Academy of Dermatology and Venereology” This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.
54 citations
,
February 2010 in “British Journal of Dermatology” This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.
77 citations
,
April 2009 in “British Journal of Dermatology” In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.
26 citations
,
April 2009 in “Australasian Journal of Dermatology” In this study, a 9-year-old girl with female pattern hair loss showed clinical improvement and hair regrowth after six months of daily oral spironolactone.
47 citations
,
September 2008 in “British Journal of Dermatology” This study found that women with androgenetic alopecia experience diffuse hair loss due to a decrease in terminal hairs and an increase in vellus hairs per follicular unit.
14 citations
,
January 2008 in “Dermatology Online Journal” This review discusses the use of anti-hormonal therapies for female androgenetic alopecia and notes that while some treatments show promise, larger controlled studies are needed to define their roles and effectiveness.
215 citations
,
November 2006 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.
100 citations
,
June 2006 in “British Journal of Dermatology” This study found that as hair loss severity increased in women with female pattern hair loss, the number of vellus follicles also rose, indicating miniaturization of terminal hair follicles.
108 citations
,
March 2006 in “Archives of Dermatology” This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.
33 citations
,
October 2005 in “PubMed” In this case study, significant improvement in androgenic alopecia was observed in a 46-year-old woman after 9 months of treatment with dutasteride following limited success with finasteride.
179 citations
,
March 2005 in “British Journal of Dermatology” This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.
130 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that estrogen receptor beta, not alpha, is the main mediator of estrogen action in human skin and hair follicles, suggesting a distinct role in these tissues.
139 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This article reviews androgenetic alopecia in women, highlighting diagnosis criteria and noting that topical minoxidil is currently the only proven treatment for hair growth; it reports no clinical trial findings.
118 citations
,
May 2003 in “Toxicological Sciences” This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.
164 citations
,
January 2003 in “Drugs”
108 citations
,
January 2003 in “Fertility and Sterility” This study found that flutamide at 250 mg daily modestly improved hair thinning in premenopausal women with hyperandrogenic alopecia over one year, while cyproterone acetate and finasteride were not effective.
165 citations
,
December 2002 in “Molecular and Cellular Endocrinology” This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.
174 citations
,
November 2002 in “Expert Reviews in Molecular Medicine” This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.
46 citations
,
September 2002 in “Journal of the European Academy of Dermatology and Venereology” In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.
94 citations
,
August 2002 in “Experimental Dermatology” This study found that 17α‐estradiol increases aromatase activity in female hair follicles, which may explain its beneficial effects in treating androgenetic alopecia.
149 citations
,
June 2002 in “British Journal of Dermatology” Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.
138 citations
,
March 2001 in “Clinics in Dermatology” This review discusses the relationship between perceived stress and hair loss or graying, exploring hair follicles as a model system but reports no new clinical results.
239 citations
,
November 2000 in “Journal of The American Academy of Dermatology” In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.
110 citations
,
September 1999 in “British Journal of Dermatology” This case report describes a young woman with hypopituitarism who experienced hair loss typical of female androgenetic alopecia without detectable androgens, suggesting this hair loss pattern may not always be androgen dependent.
16 citations
,
January 1989 in “Springer eBooks” Cyproterone acetate effectively treats female hair loss by increasing healthy hair and decreasing unhealthy hair, but doesn't change hair thickness.
28 citations
,
March 1973 in “The Journal of Clinical Endocrinology & Metabolism” This study found that hair follicles from balding men show significant metabolic differences compared to those from non-balding individuals, particularly in their ability to process dehydroepiandrosterone.